Archive for the ‘Gene Therapy Research’ Category

St. Louis, MO (PRWEB) January 17, 2014

Also called individualized or customized medicine, personalized medicine is an innovative subcategory of medicine that the FDA has recognized as topic of focus for treating diseases such as mesothelioma cancer. According to Harvard Medical Schools Partners Healthcare Center for Personalized Genetic Medicine (PCPGM), personalized medicine is the ability to determine an individual's unique molecular characteristics and to use those genetic distinctions to:

Individualized diagnosis, treatment, and prevention are crucial to the fight against mesothelioma and other types of cancers, said Neil Maune, partner at MRHFM. With the FDAs support, we hope that more funding and wide-spread information about personalized medicine for patients will be accessible in the United States.

In a 61-page report titled "Paving the Way for Personalized Medicine: FDA's Role" that was published on the FDAs website in October 2013, the organization states that it plans to help further personalized medicine by focusing on advanced regulatory science. Thanks to this commitment, a number of breakthroughs in genetic research have made it possible for researchers to target specific genetic mutations, which will help lead them to new and more effective mesothelioma treatments. While a traditional approach to mesothelioma treatment may very well be effective in some cases, researchers say that if treatment is more individualized based on the patients unique, specific traits, it will fulfill its purpose to better diagnose an individual's disease, reduce adverse reactions, and increase the chances of a positive outcome following treatment. You can find more information on mesothelioma treatment options at http://www.mesotheliomabook.com.

This individual approach to treatment will also minimize or eliminate the need to participate in experimental treatments and ease patient fears based on the idea that a personalized treatment path offers more promise than a one-size-fits-all approach to treating mesothelioma.

The law firm of MRHFM focuses exclusively on mesothelioma cases and works to educate the public about the mesothelioma industry and advancements in treatment for mesothelioma cancer. The law firm advocates for mesothelioma research also offers a free book about mesothelioma titled 100 Questions & Answers About Mesothelioma that is available for request online at http://www.mesotheliomabook.com.

About Maune Raichle Hartley French & Mudd, LLC Maune Raichle Hartley French & Mudd, LLC is a mesothelioma law firm based in St. Louis, MO. With offices across the country, their size and exclusive focus on mesothelioma cases allows them to represent clients through the process as quickly as possible and maximize their clients recovery. The attorneys at MRHFM have represented thousands of victims exposed to asbestos. The firm has 29 attorneys across the country, 16 investigators, 7 client service managers, and additional support staff including paralegals and legal assistants. For more information about Maune Raichle Hartley French & Mudd, LLC, visit http://www.mesotheliomabook.com.

Read more here:
MRHFM and the FDA Support Personalized Medicine for Mesothelioma

Lecture 7: How genetics can contribute to Conservation

By: HimalayanTigers

Read the original:
Lecture 7: How genetics can contribute to Conservation - Video

Lecture 5: Conservation Genetics

By: HimalayanTigers

View post:
Lecture 5: Conservation Genetics - Video

Closing Ceremony of the Course #39;Conservation Biology and Wildlife Genetics #39;
A course #39;Conservation Biology and Wildlife Genetics #39; at the Kathmandu University, organised and sponsored by the Himalayan Tiger Foundation. See also http://www.hi...

By: HimalayanTigers

View original post here:
Closing Ceremony of the Course 'Conservation Biology and Wildlife Genetics' - Video

Operning Ceremony of the Course #39;Conservation Biology and Wildlife Genetics #39;

By: HimalayanTigers

Original post:
Operning Ceremony of the Course 'Conservation Biology and Wildlife Genetics' - Video

By RTT News, January 17, 2014, 09:56:00 AM EDT

(RTTNews.com) - Seattle Genetics Inc. ( SGEN ) announced Friday that its collaborator, Takeda Pharmaceutical Company Limited (TKPYY.PK, TKPHF.PK), has received approval of Adcetris (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma (HL) and anaplastic large cell lymphoma or ALCL.

As a result, Seattle Genetics will receive two milestone payments from Takeda totaling $9 million upon final pricing agreement in Japan. Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including ALCL.

"ADCETRIS is now approved in 39 countries, and we continue to work with our collaborator, Takeda, to expand regulatory approvals globally," said Clay Siegall, President and Chief Executive Officer of Seattle Genetics.

The approval of the new drug application was based on two global pivotal phase 2 clinical trials of Adcetris, as well as a phase 1/2 clinical trial conducted in Japan, for patients with relapsed or refractory CD30-positive HL and ALCL.

In March 2012, the Japanese MHLW granted Adcetris orphan drug designation for the treatment of patients with HL and ALCL, which triggered priority review in Japan.

Seattle Genetics and Takeda are jointly developing Adcetris. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize Adcetris in the rest of the world.

Seattle Genetics and Takeda are funding joint development costs for Adcetris on a 50:50 basis, except in Japan where Takeda will be solely responsible for development costs. Seattle Genetics is entitled to royalties based on a percentage of Takeda's net sales in its territory at rates that range from the mid-teens to the mid-twenties based on sales volume, subject to offsets for royalties paid by Takeda to third parties.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Continued here:
Seattle Genetics: Takeda Gets Approval For Adcetris In Japan

Dennis Thompson HealthDay Reporter Posted: Thursday, January 16, 2014, 2:00 PM

THURSDAY, Jan. 16, 2014 (HealthDay News) -- A new gene therapy that successfully treated a rare eye disease in clinical trials could prove the key to preventing more common inherited causes of blindness, researchers say.

In six male patients, doctors used a virus to repair a defective gene that causes choroideremia, a degenerative eye disease that can lead to complete blindness by middle age, according to a clinical trial report published online Jan. 16 in The Lancet.

Vision improved for all the patients following the gene therapy, and particularly for two patients with advanced choroideremia, said lead author Robert MacLaren of the Nuffield Laboratory of Ophthalmology at the University of Oxford, and a consultant surgeon at the Oxford Eye Hospital, in England.

"In truth, we did not expect to see such dramatic improvements in visual acuity and so we contacted both patients' home opticians to get current and historical data on their vision in former years, long before the gene therapy trial started," MacLaren said in a university news release. "These readings confirmed exactly what we had seen in our study and provided an independent verification."

While choroideremia is a rare disease, affecting about one in every 50,000 people, doctors believe the process used to treat it could be turned toward more common inherited eye disorders, such as macular degeneration or retinitis pigmentosa.

"This is something that we've been trying to accomplish for years in retinal science, and it's very encouraging," said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital, in New York City.

Fromer, who was not involved with the new research, predicted that gene therapy could in the future be used to prevent blindness by fixing defective genes in patients before something like macular degeneration can even take root.

"We'll go from putting a Band-Aid on the lesion to preventing it from happening. This is a new pathway to fix things before they get broken," said Fromer, who is also the eye surgeon for the National Hockey League's New York Rangers

View post:
Gene Therapy May Restore Sight in People With Rare Blinding Disease

Harold Schmeck Pines, Maya, ed. "Blazing the Genetic Trail." Bethesda, MD: Howard Hughes Medical Institute, 1991.

The eminent British molecular biologist Sydney Brenner once got a hearty laugh from his audience by describing how some future graduate student will define a mouse: "ATC, GCC, AAG, GGT, GTA, ATA. . . ." But every year the idea of defining an organism by the sequence of its DNA bases seems a little less farfetched.

Victor McKusick, of The Johns Hopkins University School of Medicine, notes that scientists' growing ability to read and write in the language of the genes has already explained some of the once-mysterious basic concepts of genetics. The difference between dominant and recessive traits as causes of genetic disease used to be just an abstraction based on a great deal of observation. If a genetic defect expressed itself only in patients who inherited the trait from both parents, it was called recessive; both copies of the gene coding for the trait were presumably defective, resulting in disease. If the trait was dominant, on the other hand, it meant that one defective copy of the gene was sufficient to spell disaster.

But why should some disorders require two mistakes, while others resulted from only one? Molecular biology has given a concrete and remarkably simple explanation.

"It now appears that these two categories [recessive and dominant] correspond pretty closely to the two fundamental categories of proteins: enzymatic and structural," McKusick said in a recent review of genetics research. Recessive disorders tend to result from failures in genes that code for enzymes, the biological catalysts that do much of the body's chemical work. A person who has inherited the defective gene from only one parent often goes disease-free because the normal gene inherited from the other parent produces enough of the enzyme to serve the body's needs. The disorder appears only when the person inherits the same defect from both parents and therefore lacks any working copy of the normal gene.

If the genetic defect affects structural proteins, however, for example, collagen, a key component of connective tissues and bones, one copy of the faulty gene is usually enough to cause disease. It is easy to see why. A four-engine airplane can still fly even if one of its engines fails, as long as the other engines provide enough power, but a single faulty strut that makes a wing fall off will cause the plane to crash.

The reason some genetic disorders are relatively common while most are extremely rare has also proved to be almost ridiculously obvious. The bigger the gene, the greater the chance that something will go wrong with part of it. In many cases, it seems as simple as that.

Sometimes rather subtle differences in the defects of a single gene can make a profound difference in a patient's fate, as Louis Kunkel of the HHMI unit at Harvard University learned after he and his team discovered the gene for Duchenne muscular dystrophy (DMD) in 1986. Major flaws in that huge gene result in the presently incurable DMD, a muscle-wasting disease that leaves young boys wheelchair-bound by age 12 and generally kills them by age 20, because the muscles that control breathing fail. By contrast, lesser defects in that same gene produce a much more benign disease, Becker's muscular dystrophy.

A year after discovering this gene, the team identified the protein it codes for - a previously unknown protein, now named dystrophin, which occurs in muscles in such small amounts that it would never have been found by ordinary means. Dystrophin plays a key role in muscle cells and may be involved in many other muscle diseases. Researchers are now analyzing how dystrophin functions, what other proteins it interacts with, and whether it might be replaced to interrupt the course of disease.

Experts see many more insights such as these in the future, as research in molecular genetics opens some of the "black boxes" of biology.

Read more:
The Future Of Genetic Research - Access Excellence

PUBLIC RELEASE DATE:

16-Jan-2014

Contact: Cody Mooneyhan cmooneyhan@faseb.org 301-634-7104 Federation of American Societies for Experimental Biology

Research involving rats suggests that there is a biological link between paternal diet, bodyweight and health at the time of conception and the health of his offspring. In a new research report published online in The FASEB Journal, scientists show that if male rats ate a high fat diet, had diabetes and were obese, their offspring had altered gene expression in two important metabolic tissues--pancreas and fat (even though they were not yet obese). This altered gene expression may increase the risk of future obesity and premature aging. Other genes that were affected include markers of premature aging, cancer, and chronic degenerative disease.

"While scientists have focused on how the maternal diet affects children's health, this study is part of exciting new research exploring the impact of paternal diet on offspring risk of obesity," said Margaret Morris, Ph.D., a researcher involved in the work from the Pharmacology School of Medical Sciences at the University of New South Wales in Sydney, Australia. "The fact that similar gene markers were affected in pancreas and fat tissue tells us that some of the same pathways are being influenced, possibly from the earliest stages of life. It will be important to follow up these findings, and to learn more about when and how to intervene to reduce the impact of poor paternal metabolic health on offspring."

To make this discovery, Morris and colleagues used two groups of male rats, one of which was obese and diabetic and fed a high-fat diet; and the other was lean and healthy and fed a normal diet. The two groups of males were mated with lean female rats, and researchers examined their female offspring. Those who were born from obese fathers on a high-fat diet, showed a poor ability to respond to a glucose challenge, even while consuming a healthy diet. Specifically, the offspring of the obese rats showed gene expression changes in pancreatic islets, which are responsible for producing insulin to control blood glucose and the fat tissue of their female offspring.

"For a long time, we've known that the nutrition and health status of women who are pregnant or who want to get pregnant is critical to the health of her offspring, and we've also suspected that the same is true for fathers to a lesser degree," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This report is the first step in understanding exactly how the nutrition and health of fathers affects his children, for better or worse."

###

Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the most cited biology journals worldwide according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.

FASEB is composed of 27 societies with more than 110,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

Read the original post:
Fathers' diet, bodyweight and health at conception may contribute to obesity in offspring

Artificial manipulation, modification, and recombination of DNA or other nucleic-acid molecules in order to modify an organism or population of organisms. The term initially meant any of a wide range of techniques for modifying or manipulating organisms through heredity and reproduction. Now the term denotes the narrower field of recombinant-DNA technology, or gene cloning, in which DNA molecules from two or more sources are combined, either within cells or in test tubes, and then inserted into host organisms in which they are able to reproduce. This technique is used to produce new genetic combinations that are of value to science, medicine, agriculture, or industry. Through recombinant-DNA techniques, bacteria have been created that are capable of synthesizing human insulin, human interferon, human growth hormone, a hepatitis-B vaccine, and other medically useful substances. Recombinant-DNA techniques, combined with the development of a technique for producing antibodies in great quantity, have made an impact on medical diagnosis and cancer research. Plants have been genetically adjusted to perform nitrogen fixation and to produce their own pesticides. Bacteria capable of biodegrading oil have been produced for use in oil-spill cleanups. Genetic engineering also introduces the fear of adverse genetic manipulations and their consequences (e.g., antibiotic-resistant bacteria or new strains of disease). See also biotechnology, molecular biology.

Original post:
Genetic engineering - Definition and More from the Free ...

Genetic Engineering: Challenging our perspectives on reproduction by Dr. Gary Fritz

By: Wafeek Wahby

Continued here:
Genetic Engineering: Challenging our perspectives on reproduction by Dr. Gary Fritz - Video

Advanced Genetics Mod Review
Villagers trap me on mod island and I am quarantined. But I #39;m in a lab so i take advantage of the situation and use my surroundings to escape. Download: http...

By: Prince Bosco

Read the original post:
Advanced Genetics Mod Review - Video

PPG Commercial 2014
Paw Print Genetics 2014 commercial.

By: Paw Print Genetics

More:
PPG Commercial 2014 - Video

Epilepsy genetics: the impact on clinical practice - Ingrid Scheffer
Epilepsy genetics: the impact on clinical practice - Ingrid Scheffer International League Against Epilepsy http://www.ilae.org International Bureau for Epilepsy http://www...

By: epilepsycongress

Read this article:
Epilepsy genetics: the impact on clinical practice - Ingrid Scheffer - Video

Gene therapy improves vision for patients facing blindness
Medical researchers in Oxford say they have managed to improve the sight of patients who were going blind because of a rare genetic disorder. Genes are injec...

By: fairfest

See the rest here:
Gene therapy improves vision for patients facing blindness - Video

Gene therapy is the insertion of genes into an individual's cells and tissues to treat a disease, and hereditary diseases in which a defective mutant allele is replaced with a functional one.

Although the technology is still in its infancy, it has been used with some success.

Antisense therapy is not strictly a form of gene therapy, but is a genetically-mediated therapy and is often considered together with other methods.

In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal," disease-causing gene.

A carrier called a vector must be used to deliver the therapeutic gene to the patient's target cells.

Currently, the most common type of vectors are viruses that have been genetically altered to carry normal human DNA.

Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner.

Scientists have tried to harness this ability by manipulating the viral genome to remove disease-causing genes and insert therapeutic ones. Target cells such as the patient's liver or lung cells are infected with the vector.

The vector then unloads its genetic material containing the therapeutic human gene into the target cell.

The generation of a functional protein product from the therapeutic gene restores the target cell to a normal state. In theory it is possible to transform either somatic cells (most cells of the body) or cells of the germline (such as sperm cells, ova, and their stem cell precursors).

View post:
Gene therapy - Science Daily

By delivering gene therapies to patients before they go blind, doctors may be able to prevent the loss of many important light-detecting cells.

Light preserver: Robert MacLaren performs retinal surgery on a patient participating in a gene therapy experiment at the Oxford University Eye Hospital.

A new kind of gene therapy has reversed some vision loss in people born with a degenerative eye disease for which there is no existing treatment.

In a first for the field, the treatment can be given to some participants who still had 20/20 vision, albeit in a limited field of vision. By delivering gene therapy at an earlier stage, researchers hope to save more light-sensing cells in the retina.

We need to push gene therapy forward, to apply it before vision is gone, says Robert MacLaren, an ophthalmologist at the University of Oxford who led the study. When retinal damage gets to a certain point, its beyond repair.

MacLaren says earlier treatment could also be particularly important for conditions such as retinitis pigmentosa and age-related macular degeneration.

The surgical procedure employed put the precious remaining vision of patients in the trial at risk because it involved detaching delicate retina tissue in one of each participants eyes, but so far no problems have occurred since that surgery, the researchers report. Some participants report that theyre now able to detect more light, read more letters and numbers, and even see the stars at night. One patient, who before his treatment could not read any lines on an eye chart with his most affected eye, was able to read three lines with that eye following his treatment.

The condition addressed in the work is choroideremia, an eye disease that affects an estimated one in every 50,000 people. Because the gene that causes this disease is on the X chromosome, it primarily affects males. Starting in late childhood usually, the condition causes progressive narrowing or tunneling of vision and often ends in blindness. The condition gradually wipes out the light-detecting rods and cones in the retina.

The experimental treatment adds a working copy of the culpable gene to the retinal cells of patients born with a defective copy. The trial also involved an experimental way of delivering gene therapy to the eye. Each patients retina was first lifted, and the gene therapy was injected into the space created under the retina. MacLaren and colleagues report on the condition of six patients in a study published on Wednesday in the Lancet.

Other groups are also developing gene therapies for retinal diseases. This includes a group at Childrens Hospital of Philadelphia, which recently funded a new company to continue human trials of a treatment for Lebers Congenital Amaurosis, another inherited form of retinal degeneration (see New Gene Therapy Company Launches).

See the original post here:
Gene Therapy Tested as a Way to Stop Blindness

Last Updated Jan 16, 2014 11:10 PM EST

Sixty-two-year-old Jonathan Wyatt was diagnosed at age 20 with choroideremia, a rare genetic disorder that causes progressive blindness. In recent years, he was unable to read. He was one of six patients in the gene therapy trial.

Jonathan Wyatt was diagnosed at age 20 with choroideremia, a rare genetic disorder that causes progressive blindness

CBS News

People with the disease lack a gene that helps the eye make a protein needed for normal vision. When scientists injected a copy of that gene into the eye, the retinal cells started producing the protein. All six patients had improved vision and two, including Wyatt, had dramatic results.

Robert Maclaren of Oxford University led the study.

Rather than taking a pill or proteins or tablets, were actually correcting the disease at the genetic level, Maclaren said. In other words, genetically modifying the patients who have the problems to put the gene back thats missing.

"Well, this is a game changer because this is something that's been hypothesized and worked on for almost two decades, Schwartz told CBS News. The eye is the perfect organ into which gene therapy can begin to be successful because it's small, the amount of medication that needs to go into the eye is low, it's relatively safe.

One way this therapy could be useful in patients with macular degeneration is to eliminate the need for monthly injections of drugs into the eye. A single gene treatment could teach the eye to produce the medicine itself, but more testing is needed.

Follow this link:
Gene therapy has clear results for seeing-impaired

San Diego, CA (PRWEB) January 16, 2014

The makers of Ovation, the nationwide provider of luxurious hair care products, is showing their love for Valentines Day with a promotional gift set that is sure to make customers hearts skip a beat.

Ovation Hair recently announced their Valentines Gift Set promotion which includes a 10% savings on any 6oz Cell Therapy System plus a bonus of refreshing bath crystals boxed in a heart shaped tin.

We love to pamper our customers at Ovation explains Erika Sherwood, Marketing Manager at Ovation Hair. This Valentines Day Gift Set is the perfect match - delivering a sweet price and gift with purchase.

The Ovation Valentines Gift Sets go on sale this week at OvationHair.com and via phone at 888.411.3252 while supplies last.

Each 6oz Cell Therapy System includes a bottle of their flagship product Ovation Cell Therapy, Shampoo and a Crme Rinse. In addition to the sets savings, customers will also receive bath crystals and a sample packet of Ovations Clarifying Shampoo.

About Ovation The philosophy of Ovation Hair is to meet clients high expectations with quality, nourishing and rejuvenating products that demonstrate proven effectiveness. Ovation products include high quality ingredients, proven to be safe and effective to create healthy hair. The hair care products are developed as a natural system designed to rejuvenate hair to look thicker, stronger and longer. For more information, visit http://www.ovationhair.com.

Also find Ovation on: http://www.twitter.com/ovationhair http://www.facebook.com/ovationhair http://www.youtube.com/ovationhair

See original here:
Ovation Hair® Sweetens Valentine’s Day with Exclusive Gift Set

Scientists hope early intervention with the surgical treatment will halt progression of the devastating disorder, choroideremia, before patients are robbed of their sight.

It is the first time gene therapy has successfully been applied to the light-sensitive photoreceptors of the retina, the digital camera at the back of the eye.

Preliminary results from the first six patients taking part in a Phase One trial surprised and delighted the Oxford University team.

Although the trial was only designed to test safety and dosages, two men with relatively advanced disease experienced dramatic improvements to their eyesight.

The researchers are now planning a larger Phase II trial that will focus on the therapy's effectiveness.

Professor Robert MacLaren, who led the gene therapy operations at Oxford Eye Hospital, said: "We're absolutely delighted with the results so far.

"It is still too early to know if the gene therapy treatment will last indefinitely, but we can say that the vision improvements have been maintained for as long as we have been following up the patients, which is two years in one case.

"In truth, we did not expect to see such dramatic improvements in visual acuity and so we contacted both patients' home opticians to get current and historical data on their vision in former years, long before the gene therapy trial started.

"These readings confirmed exactly what we had seen in our study and provided an independent verification."

The ground-breaking research could pave the way to gene therapy treatments for more common blinding conditions, including age-related macular degeneration and retinitis pigmentosa, another inherited disease.

See more here:
Gene therapy gives sight back to patients due to go blind

How to solve dihybryd cross genetics problems - step by step
s I said in part I of these tips and instructions, all genetics problems are solved according to the same pattern. When we complicate the problem by followin...

By: GeneticsLessons

More:
How to solve dihybryd cross genetics problems - step by step - Video

Genetics and Major Psychological Disorders: A Course for Genetic Advisors
Mood Disorder Nos Symptoms http://tinyurl.com/Mood-Disorder-Nos-Symptoms mood disorder nos symptoms mood disorder nos mood disorder nos dsm code episodic moo...

By: Logan ESanchez

Go here to read the rest:
Genetics and Major Psychological Disorders: A Course for Genetic Advisors - Video

How to apply Hardy-Weinberg formula in order to solve genetics problems
The Hardy-Weinberg Equation To estimate the frequency of alleles in a population, we can use the Hardy-Weinberg equation. According to this equation: p = the...

By: GeneticsLessons

See the rest here:
How to apply Hardy-Weinberg formula in order to solve genetics problems - Video

XCOM Enemy Within #25 Soldiers Genetics, Start Of The True War
Time to check out what all the fuss is about with Soldier Genetics, time to show the aliens a bit of their own medicine! Comment, like subscribe, give feed...

By: SmashGaming999

Go here to read the rest:
XCOM Enemy Within #25 Soldiers Genetics, Start Of The True War - Video

For patients with choroideremia a rare form of progressive blindness there are no current treatment options that can help stop their visual degeneration. But now a new innovative procedure may be the key.

In a new study published in The Lancet, researchers used a novel gene therapy technique on choroideremia patients, which helped restore some of the sight they had already lost over the years. Gene therapy involves injecting patients with a vital gene that is either missing or defective in their genetic code.

Gene therapy is exciting; its a new type of medicine, lead author Robert MacLaren, a professor at the University of Oxford, told FoxNews.com. And what were doing is it on a very small scale, because were looking at a very straightforward gene to replace.

Caused by a mutation in the CHM gene on the X chromosome, choroideremia causes progressive blindness due to degeneration of the choroid, retinal pigment epithelium and retina. Patients with this disease can start their lives with perfect vision, but eventually start to experience problems with light sensitivity and peripheral vision as they age.

The condition, which affects 1 in every 50,000 people, ultimately leads to the death of the photoreceptor cells in the retina causing complete blindness in middle age.

Its like looking down through a telescope at a small central island of vision, MacLaren explained of the disorder. And by the time theyre in their 40s and 50s, they lose vision completely.

Because choroideremia is caused by a defect in a single gene, MacLaren believed that gene therapy could hold promise for patients with this form of progressive blindness. Additionally, because the cellular degeneration occurs so slowly, the researchers had a large window of opportunity in which they could test their treatment before complete visual loss occurred.

In order to fix the mutation found in choroideremia patients, MacLaren and his colleagues genetically altered an adeno-associated virus (AAV), so that it carried a corrective copy of the CHM gene.

The virus is a small biological organism, and its very good at getting into cells, MacLaren said. But rather than deliver the viruss DNA, weve taken out most of the viral DNA and instead put in the missing gene. So it releases the DNA into the nucleus its a single stranded DNA with the missing [CHM] gene.

The researchers injected their engineered virus into the retinas of six patients between the ages of 35 and 63, all of whom were experiencing different stages of choroideremia. Four of the patients still had good eyesight, though they had almost no peripheral vision, and the other two patients had already started to experience vision loss.

See the original post here:
Gene therapy trial shows promise in treating rare form of blindness